pcDNA3-sACE2(WT)-Fc(IgG1) Citations (8)
Originally described in: Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E Science. 2020 Sep 4;369(6508):1261-1265. doi: 10.1126/science.abc0870. Epub 2020 Aug 4. PubMed Journal
Articles Citing pcDNA3-sACE2(WT)-Fc(IgG1)
| Articles |
|---|
| The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2. Procko E. bioRxiv. 2020 May 11. doi: 10.1101/2020.03.16.994236. PubMed |
| Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Bosnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, Ravens I, Ritter C, Schultze-Florey CR, Godecke N, Martens J, Kleine-Weber H, Hoffmann M, Cossmann A, Yilmaz M, Pink I, Hoeper MM, Behrens GMN, Pohlmann S, Blasczyk R, Schulz TF, Forster R. Cell Mol Immunol. 2021 Apr;18(4):936-944. doi: 10.1038/s41423-020-00573-9. Epub 2020 Nov 2. PubMed |
| Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. Dickey TH, Tang WK, Butler B, Ouahes T, Orr-Gonzalez S, Salinas ND, Lambert LE, Tolia NH. bioRxiv. 2021 May 10. doi: 10.1101/2021.05.09.443238. PubMed |
| Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model. Shrivastava T, Singh B, Rizvi ZA, Verma R, Goswami S, Vishwakarma P, Jakhar K, Sonar S, Mani S, Bhattacharyya S, Awasthi A, Surjit M. Front Immunol. 2021 May 24;12:641447. doi: 10.3389/fimmu.2021.641447. eCollection 2021. PubMed |
| Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. Capraz T, Kienzl NF, Laurent E, Perthold JW, Foderl-Hobenreich E, Grunwald-Gruber C, Maresch D, Monteil V, Niederhofer J, Wirnsberger G, Mirazimi A, Zatloukal K, Mach L, Penninger JM, Oostenbrink C, Stadlmann J. Elife. 2021 Dec 20;10. pii: 73641. doi: 10.7554/eLife.73641. PubMed |
| Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. Dickey TH, Tang WK, Butler B, Ouahes T, Orr-Gonzalez S, Salinas ND, Lambert LE, Tolia NH. Sci Adv. 2022 Sep 16;8(37):eabq8276. doi: 10.1126/sciadv.abq8276. Epub 2022 Sep 14. PubMed |
| Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells. Kumar CS, Singh B, Rizvi ZA, Parray HA, Verma JK, Ghosh S, Mukhopadhyay A, Awasthi A, Shrivastava T, Banerjee M. ACS Infect Dis. 2022 Oct 14;8(10):2119-2132. doi: 10.1021/acsinfecdis.2c00217. Epub 2022 Sep 21. PubMed |
| Tetherin antagonism by SARS-CoV-2 ORF3a and spike protein enhances virus release. Stewart H, Palmulli R, Johansen KH, McGovern N, Shehata OM, Carnell GW, Jackson HK, Lee JS, Brown JC, Burgoyne T, Heeney JL, Okkenhaug K, Firth AE, Peden AA, Edgar JR. EMBO Rep. 2023 Dec 6;24(12):e57224. doi: 10.15252/embr.202357224. Epub 2023 Oct 11. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.